---
title: "CLRB Q1'26 Earnings: EPS estimate is (1.89) USD"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/285928586.md"
description: "CLRB (Cellectar Biosciences, Inc.) is set to announce its Q1'26 results on May 12, time not specified. The earnings are expected to be disclosed at 8:00 AM ET (12:00 PM UTC).For Q1'26, revenue estimate is 0 USD with EPS (earnings per share) anticipated at (1.89) USD. Learn more details at .Revenue & EPS values are provided in USDQ1'25Q2'25Q3'25Q4'25Q1'26Revenue Reported—————Revenue Estimate—————Revenue SurpriseEPS Reported(4.20)(3.39)(1.41) 0.65EPS Estimate(4.90)(3.72)(2.53)(1.22)(1.89) EPS Surprise+14.29%+8.85%+44.20%+153.07%DisclaimerSelect reference data provided by FactSet. Copyright © 2026 FactSet Research Systems Inc."
datetime: "2026-05-11T11:00:30.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/285928586.md)
  - [en](https://longbridge.com/en/news/285928586.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/285928586.md)
---

# CLRB Q1'26 Earnings: EPS estimate is (1.89) USD

CLRB (Cellectar Biosciences, Inc.) is set to announce its Q1'26 results on May 12, time not specified. The earnings are expected to be disclosed at 8:00 AM ET (12:00 PM UTC).

For Q1'26, revenue estimate is 0 USD with EPS (earnings per share) anticipated at (1.89) USD. Learn more details at .

**Revenue & EPS values are provided in USD**

Q1'25

Q2'25

Q3'25

Q4'25

Q1'26

**Revenue Reported**

—

—

—

—

—

**Revenue Estimate**

—

—

—

—

—

**Revenue Surprise**

**EPS Reported**

(4.20)

(3.39)

(1.41)

0.65

**EPS Estimate**

(4.90)

(3.72)

(2.53)

(1.22)

(1.89)

**EPS Surprise**

+14.29%

+8.85%

+44.20%

+153.07%

**Disclaimer**

Select reference data provided by FactSet. Copyright © 2026 FactSet Research Systems Inc.

### Related Stocks

- [CLRB.US](https://longbridge.com/en/quote/CLRB.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [IXJ.US](https://longbridge.com/en/quote/IXJ.US.md)
- [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md)
- [XLV.US](https://longbridge.com/en/quote/XLV.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [VHT.US](https://longbridge.com/en/quote/VHT.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)

## Related News & Research

- [Full Transcript: Cellectar Biosciences Q1 2026 Earnings Call](https://longbridge.com/en/news/286422585.md)
- [Shah Capital Management Will Vote ‘No' Across Five Proposals On Novavax's June 18 Ballot - SEC Filing](https://longbridge.com/en/news/286565204.md)
- [Eton Secures U.S. IMPAVIDO Rights; $4.25M Fees, Up To $4M Milestones And 50-55% Revenue Share](https://longbridge.com/en/news/286966420.md)
- [Relay's treatment shown to shrink vascular malformations in mid-stage trial](https://longbridge.com/en/news/286890329.md)
- [Tiziana Announces New Positive Clinical Data For Intranasal Foralumab In Non-Active Secondary Progressive Multiple Sclerosis](https://longbridge.com/en/news/286899753.md)